title: Impairment of the sarcolemmal phospholipase D-phosphatidate phosphohydrolase pathway in diabetic cardiomyopathy.
abstract: Experimental evidence suggests that the myocardial phospholipase D (PLD)-phosphatidate phosphohydrolase (PAP) signalling pathway may regulate Ca2+ movements and contractile performance of the heart. As abnormal Ca2+ homeostasis is associated with diabetic cardiomyopathy, we examined the functional status of the PLD/PAP pathway in sarcolemmal (SL) membranes isolated from insulin-dependent diabetic rat hearts at 8 weeks after a single i.v. injection of streptozotocin (65 mh/kg b.w.). Compared to age-matched controls, SL PLD hydrolytic (producing phosphatidic acid, PtdOH) and transphosphatidylation activities were significantly depressed in diabetic animals, while SL PAP was significantly augmented. The net effect of the altered enzyme activities in diabetic animals was a severely diminished (by 67% of controls) membrane level of PLD-derived PtdOH. Two weeks of insulin therapy to the 6 week diabetic animals normalized PLD, while PAP activity and PtdOH level were significantly modified, but had not completely reverted to control values. The observed changes were not due to hypothyroidism associated to the diabetic model as the induction of hypothyroidism in healthy non-diabetic animals did not affect SL PLD and PAP. The results suggest that the severe reduction of PLD-derived PtdOH and increased production of sn-1,2-diacylglycerol by phosphatidate phosphohydrolase may lead to an impairment of the bioprocesses mediated by these signalling lipids.
authors.affiliation: Institute of Cardiovascular Sciences, St Boniface General Hospital Research Centre, Winnipeg, Canada.
authors.forename: S A
authors.initials: SA
authors.lastname: Williams
authors.forename: P S
authors.initials: PS
authors.lastname: Tappia
authors.forename: C H
authors.initials: CH
authors.lastname: Yu
authors.forename: M
authors.initials: M
authors.lastname: Bibeau
authors.forename: V
authors.initials: V
authors.lastname: Panagia
mesh_terms: D000818:Animals; D009202:Cardiomyopathies / Q000201:enzymology*; D003921:Diabetes Mellitus, Experimental / Q000139:chemically induced / Q000188:drug therapy / Q000201:enzymology*; D004075:Diglycerides / Q000378:metabolism; D004791:Enzyme Inhibitors; D005459:Fluorides / Q000494:pharmacology; D007037:Hypothyroidism / Q000139:chemically induced / Q000201:enzymology; D007328:Insulin / Q000627:therapeutic use; D008297:Male; D009206:Myocardium / Q000201:enzymology; D010711:Phosphatidate Phosphatase / Q000037:antagonists & inhibitors / Q000378:metabolism*; D010739:Phospholipase D / Q000378:metabolism*; D017680:Potassium Compounds / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012508:Sarcolemma / Q000201:enzymology*; D015398:Signal Transduction / Q000502:physiology; D013974:Thyroxine / Q000097:blood
chemical_list: D004075:Diglycerides; D004791:Enzyme Inhibitors; D007328:Insulin; D017680:Potassium Compounds; C033320:potassium fluoride; D010711:Phosphatidate Phosphatase; D010739:Phospholipase D; D013974:Thyroxine; D005459:Fluorides